Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study
Long-term, once-daily administration of XR was effective and safe in dyslipidemic patients with high TG. XR provided favorable TG-lowering effects regardless of morning or evening administration, and the XR dose increase proved effective in patients having initially inadequate response.
Authors
- Ayumi Saito (ORCID: https://orcid.org/0000-0001-9302-4287)
- Hideki Suganami (ORCID: https://orcid.org/0000-0001-9130-0137)
- Ryohei Tanigawa (ORCID: https://orcid.org/0009-0005-8804-2014)
- Daisuke Furukawa (ORCID: https://orcid.org/0000-0002-5383-1663)
- Shun Ishibashi (ORCID: https://orcid.org/0000-0002-1063-1979)
- Eiichi Araki (ORCID: https://orcid.org/0000-0002-4064-7525)
- Hidenori Arai (ORCID: https://orcid.org/0000-0001-6747-8680)
- Koutaro Yokote (ORCID: https://orcid.org/0000-0003-3033-4813)
- Shizuya Yamashita (ORCID: https://orcid.org/0000-0001-6645-4185)
Institutions
- Center for Global Development (US)
- Jichi Medical University (JP)
- Chiba University (JP)
- Kumamoto Health Science University (JP)
- Diabetes Australia (AU)
- Japan Hospital Association (JP)
- Kowa (Japan) (JP)
- Jichi Medical University Hospital (JP)
- National Center for Geriatrics and Gerontology (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2025-02-06
- DOI
- https://doi.org/10.5551/jat.65350
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Abbott Japan
- Kowa Company
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Astellas Pharma
- Otsuka Pharmaceutical
- Terumo
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Novartis Pharma
- Pfizer Japan
- MSD K.K.
- Eli Lilly Japan
- Bayer Yakuhin
- Novo Nordisk Pharma
- Sanofi K.K.
- Daiichi Sankyo Company
- Daiichi Sankyo Europe